John Lyons
Astex
90 Papers
479 Citations
John Lyons is an academic researcher from Astex. The author has contributed to research in topics: Kinase & Cancer. The author has an hindex of 30, co-authored 84 publications. Previous affiliations of John Lyons include Institute of Cancer Research.
Chat about Author
Papers
•Journal Article
Overexpression of AKT2/Protein Kinase Bβ Leads to Up-Regulation of β1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells
M. Jane Arboleda,John Lyons,Fairooz F. Kabbinavar,Mark R. Bray,Bryan E. Snow,Raul Ayala,Mordechai Danino,Beth Y. Karlan,Dennis J. Slamon +8 more
TL;DR: Overexpression of AKT2, but not AKT1 or AKT3, was sufficient to duplicate the invasive effects of phosphoinositide 3-OH kinase (PI3-K) transfected in breast cancer cells, indicating thatAKT2 mediates PI3- K-dependent effects on adhesion, motility, invasion, and metastasis in vivo.
469
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Neil Thompson,John Lyons +1 more
TL;DR: Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.
237
•Journal Article
Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues.
Heinz H Schmeiser,Johannes W.G. Janssen,John Lyons,Hans R. Scherf,Wolfgang Pfau,Albrecht Buchmann,Claus R. Bartram,Manfred Wiessler +7 more
TL;DR: The apparent selectivity for mutations at adenine residues in AAI induced tumors is consistent with the identification of an N6-deoxyadenosine-AAI adduct formed by reaction of AAI with DNA in vitro, suggesting that carcinogen-deocene adducts are the critical lesions in the tumor initiation by aristolochic acid.
131
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam,Fang Fang,Ali R. Özeş,Jessica Tang,Adeoluwa Adewuyi,Harold N. Keer,John Lyons,Stephen B. Baylin,Daniela Matei,Harikrishna Nakshatri,Feyruz V. Rassool,Kathy D. Miller,Kenneth P. Nephew +12 more
TL;DR: The novel combination of the next-generation DNMTi guadecitabine and the first-in-class PARPi talazoparib inhibited breast and ovarian cancers harboring either wild-type– or mutant-BRCA, supporting further clinical exploration of this drug combination in PARPi-resistant cancers.
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang Fang,Joanne M. Munck,Jessica Tang,Pietro Taverna,Yinu Wang,David F.B. Miller,Jay Pilrose,Gavin S. Choy,Mohammad Azab,Katherine S. Pawelczak,Pamela S. VanderVere-Carozza,Michael W. Wagner,John Lyons,Daniela Matei,John J. Turchi,Kenneth P. Nephew +15 more
TL;DR: In this article, SGI-110 was used to resensitize a range of platinum-resistant ovarian cancer cells to cisplatin and induced significant demethylation and reexpression of tumor suppressor genes, differentiation-associated genes, and putative drivers of ovarian cancer resistance.
95